# Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation

> **NIH NIH R01** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2020 · $675,434

## Abstract

Project Summary
The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is a unique, longitudinal,
observational cohort study of 241 autosomal dominant polycystic kidney disease (ADPKD) patients that began
in 2000. The consortium consists of researchers at University of Alabama, University of Chicago, Emory
University, University of Kansas Medical Center, Mayo Clinic, and University of Pittsburgh. The broad, long-
term objectives of CRISP are to define the natural history of the disease and to discover prognostic biomarkers
in early disease that can accurately predict long-term renal outcomes. The goals of CRISP IV are to continue
follow-up of the CRISP cohort for 5 more years so as to refine models of CKD progression and strengthen the
association between htTKV and renal outcomes, to validate disease models using existing and additional
follow-up data from the HALT PKD study, and to incorporate powerful emerging imaging, genetic and
biochemical biomarkers to improve the accuracy of prognostication for individual patients. To achieve this, the
specific aims are: Aim 1. Continue follow-up of CRISP and HALT participants. All CRISP participants that have
not reached ESRD, together with HALT Study A participants followed at CRISP sites, will be followed up with
annual serum creatinine measurements. Aim 2. Develop improved models to predict GFR trajectories and
progression to ESRD. Existing logistic regression and trajectory models will be refined and new approaches
such as artificial neural network and classification tree models developed, using CRISP data for model fitting
and HALT-A data for external validation. Aim 3. Develop novel imaging, biochemical and genetic biomarkers of
disease progression. Highly promising new biomarkers that are emerging from ancillary studies or being
developed in parallel ongoing studies at the CRISP centers, will be evaluated for their ability to improve the
accuracy of prognostic models.

## Key facts

- **NIH application ID:** 9906761
- **Project number:** 5R01DK113111-04
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** Alan S Yu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $675,434
- **Award type:** 5
- **Project period:** 2017-04-01 → 2022-03-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9906761

## Citation

> US National Institutes of Health, RePORTER application 9906761, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation (5R01DK113111-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9906761. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*